Literature DB >> 19880261

Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes.

Mario Bignardi1, Luca Cozzi, Antonella Fogliata, Paola Lattuada, Pietro Mancosu, Piera Navarria, Gaetano Urso, Sabrina Vigorito, Marta Scorsetti.   

Abstract

PURPOSE: A planning study was performed comparing volumetric modulated arcs, RapidArc (RA), fixed beam IMRT (IM), and conformal radiotherapy (CRT) with multiple static fields or short conformal arcs in a series of patients treated with hypofractionated stereotactic body radiation therapy (SBRT) for solitary or oligo-metastases from different tumors to abdominal lymph nodes. METHODS AND MATERIALS: Fourteen patients were included in the study. Dose prescription was set to 45 Gy (mean dose to clinical target volume [CTV]) in six fractions of 7.5 Gy. Objectives for CTV and planning target volume (PTV) were as follows: Dose(min) >95%, Dose(max) <107%. For organs at risk the following objectives were used: Maximum dose to spine <18 Gy; V(15Gy) <35% for both kidneys, V(36Gy) <1% for duodenum, V(36Gy) <3% for stomach and small bowel, V(15Gy) <(total liver volume--700 cm(3)) for liver. Dose-volume histograms were evaluated to assess plan quality.
RESULTS: Planning objectives on CTV and PTV were achieved by all techniques. Use of RA improved PTV coverage (V(95%) = 90.2% +/- 5.2% for RA compared with 82.5% +/- 9.6% and 84.5% +/- 8.2% for CRT and IM, respectively). Most planning objectives for organs at risk were met by all techniques except for the duodenum, small bowel, and stomach, in which the CRT plans exceeded the dose/volume constraints in some patients. The MU/fraction values were as follows: 2186 +/- 211 for RA, 2583 +/- 699 for IM, and 1554 +/- 153 for CRT. Effective treatment time resulted as follows: 3.7 +/- 0.4 min for RA, 10.6 +/- 1.2 min for IM, and 6.3 +/- 0.5 min for CRT.
CONCLUSIONS: Delivery of SBRT by RA showed improvements in conformal avoidance with respect to standard conformal irradiation. Delivery parameters confirmed logistical advantages of RA, particularly compared with IM.

Entities:  

Mesh:

Year:  2009        PMID: 19880261     DOI: 10.1016/j.ijrobp.2009.05.035

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  30 in total

Review 1.  Volumetric modulated arc therapy: a review of current literature and clinical use in practice.

Authors:  M Teoh; C H Clark; K Wood; S Whitaker; A Nisbet
Journal:  Br J Radiol       Date:  2011-11       Impact factor: 3.039

2.  RapidArc combined with the active breathing coordinator provides an effective and accurate approach for the radiotherapy of hepatocellular carcinoma.

Authors:  G Z Gong; Y Yin; L G Xing; Y J Guo; T Liu; J Chen; J Lu; C Ma; T Sun; T Bai; G Zhang; R Wang
Journal:  Strahlenther Onkol       Date:  2012-02-08       Impact factor: 3.621

3.  When is better best? A multiobjective perspective.

Authors:  Mark H Phillips; Clay Holdsworth
Journal:  Med Phys       Date:  2011-03       Impact factor: 4.071

4.  Analyzing the performance of ArcCHECK diode array detector for VMAT plan.

Authors:  Rajesh Thiyagarajan; Arunai Nambiraj; Sujit Nath Sinha; Girigesh Yadav; Ashok Kumar; Vikraman Subramani
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-02

5.  Quality assurance of RapidArc in clinical practice using portal dosimetry.

Authors:  A Fogliata; A Clivio; P Fenoglietto; J Hrbacek; S Kloeck; P Lattuada; P Mancosu; G Nicolini; E Parietti; G Urso; E Vanetti; L Cozzi
Journal:  Br J Radiol       Date:  2011-06       Impact factor: 3.039

6.  Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy.

Authors:  Marta Scorsetti; Piera Navarria; Fiorenza De Rose; AnnaMaria Ascolese; Elena Clerici; Ciro Franzese; Francesca Lobefalo; Giacomo Reggiori; Pietro Mancosu; Stefano Tomatis; Antonella Fogliata; Luca Cozzi
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-17       Impact factor: 4.553

7.  Radiotherapy with volumetric modulated arc therapy for hepatocellular carcinoma patients ineligible for surgery or ablative treatments.

Authors:  P-M Wang; W-C Hsu; N-N Chung; F-L Chang; A Fogliata; L Cozzi
Journal:  Strahlenther Onkol       Date:  2013-02-20       Impact factor: 3.621

8.  Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc.

Authors:  Marta Scorsetti; Pierina Navarria; Pietro Mancosu; Filippo Alongi; Simona Castiglioni; Raffaele Cavina; Luca Cozzi; Antonella Fogliata; Sara Pentimalli; Angelo Tozzi; Armando Santoro
Journal:  Radiat Oncol       Date:  2010-10-15       Impact factor: 3.481

9.  Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients.

Authors:  Marta Scorsetti; Antonella Fogliata; Simona Castiglioni; Caterina Bressi; Mario Bignardi; Piera Navarria; Pietro Mancosu; Luca Cozzi; Sara Pentimalli; Filippo Alongi; Armando Santoro
Journal:  Radiat Oncol       Date:  2010-10-15       Impact factor: 3.481

10.  Multicriteria optimization informed VMAT planning.

Authors:  Huixiao Chen; David L Craft; David P Gierga
Journal:  Med Dosim       Date:  2013-12-19       Impact factor: 1.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.